Labcorp Q2 revenue $3.22B (+6.2%), adj EPS $3.94; raises revenue guidance, boosts buyback $1B

LABCORP HOLDINGS INC.

2024-Q2 EPS reported $5.13 revenue$6,397,500,000

Q2 revenue $3.22B (+6.2% YoY); diluted EPS $2.43 vs $1.74; adjusted EPS $3.94 vs $3.42.
Free cash flow $432.9M vs $58.2M a year ago.
Updated FY 2024 guidance: revenue growth 6.4%-7.5% (prior 4.8%-6.4%); adj EPS $14.30-$14.90 (incl. ~$0.40 Invitae dilution).
Board approved $1.0B increase in share repurchase authorization to $1.4B; quarterly dividend $0.72/share.
Invitae acquisition expected close early August; launched FDA-approved hemophilia B CDx and preeclampsia screening.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.